ForaCare Suisse has developed the FORA COVID-19 Antigen Rapid Test, which it says provides accurate and easy-to-interpret test results for detecting an acute infection of the virus within 15 minutes. The test does not require laboratory testing and can be administered by trained experts. Clinical results indicate that the test has a 95.8% sensitivity and a 98.6% specificity, however tests have only been carried out on a small number of samples thus far.
Spectrum Solutions has partnered with Steribottle, a disposable sterile baby bottles manufacturer and distributor, to offer its SDNA-1000 saliva collection device to comply with Covid-19 testing directives in the UK. The Spectrum Solutions SDNA-1000 Saliva Collection Device was the first saliva-based solution to receive the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for COVID-19 testing.
Twist Bioscience will supply the US Centers for Disease Control and Prevention (CDC) with a customised version of the Twist SARS-CoV-2 Synthetic RNA Controls for use in the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay tests. The tests are designed to detect influenza A, B and SARS-CoV-2 from one sample.
Clear Labs has broadened the scope of its partnership with Integrated DNA Technologies (IDT), a supplier of custom nucleic acids, to automate and improve the accuracy of Covid-19 testing. Clear Labs’ sequencing platform for diagnosing the SARS-CoV-2 virus employs IDT primers as part of its solution.